Nano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer's disease via inhibiting neuropathology and modulating gut microbiota.
J Adv Res
; 35: 231-243, 2022 01.
Article
en En
| MEDLINE
| ID: mdl-35024199
Palabras clave
AD, Alzheimer's disease; APH-1, anterior pharynx-defective-1; APP, amyloid precursor protein; Aß, ß-amyloid; BACE-1, ß-site APP cleaving enzyme-1; Bcl-2, B cell lymphoma-2; CDK5, cyclin-dependent kinase 5; CMC-Na, sodium carboxymethylcellulose; Cognitive deficits; GSK-3ß, glycogen synthase kinase 3ß; Gut microbiota; HO, Honokiol; HPLC, high performance liquid chromatography; Honokiol nanoscale drug delivery system; IDE, insulin degrading enzyme; IL-1ß, interleukin 1ß; IL-6, interleukin 6; JNK, c-Jun N-terminal kinase; MCT, Medium-chain triglycerides; MWMT, Morris Water Maze test; NEP, neprilysin; NFTs, neurofibrillary tangles; Nano-HO, honokiol nanoscale drug delivery system; Neuroinflammation; PBS, phosphate-buffered saline; PDI, poly-dispersity index; PS-1, presenilin-1; ROS, reactive oxygen species; TEM, transmission electron microscope; TNF-α, tumor necrosis factor; Tau protein hyperphosphorylation; TgCRND8 mice; WT, wild type; ZP, zeta potential
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Enfermedad de Alzheimer
/
Disfunción Cognitiva
/
Microbioma Gastrointestinal
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
J Adv Res
Año:
2022
Tipo del documento:
Article